Home › Study finds key GSK-Theravance lung drug didn't extend lives
 

Keywords :   


Study finds key GSK-Theravance lung drug didn't extend lives

2015-09-09 01:33:31| Biotech - Topix.net

A closely watched study of GlaxoSmithKline plc's Breo Ellipta respiratory treatment failed to prove that it extends patients' lives, denying the drugmaker a much-needed marketing edge in its most lucrative - but declining - medicine category. It was a disappointing deja vu for the British drugmaker, which previously failed to prove the same benefit for its much older respiratory treatment Advair, long the company's top seller with revenue of $8.3 billion as recently as 2013.

Tags: key study lives drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Eastern North Pacific Tropical Weather Outlook
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 12
28.09Tropical Storm Joyce Graphics
28.09Hurricane Isaac Wind Speed Probabilities Number 12
28.09Hurricane Isaac Forecast Advisory Number 12
28.09Hurricane Isaac Public Advisory Number 12
28.09Summary for Hurricane Isaac (AT5/AL102024)
More »